ANAPTYSBIO, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ANAPTYSBIO, INC. on June 12, 2018. The filing reports on the results of the Company's 2018 Annual Meeting of Stockholders held on the same date. The registrant is an emerging growth company incorporated in Delaware.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
The primary material event reported is the outcome of the stockholder vote at the Annual Meeting. Two proposals were adopted:
- Election of Directors: Two Class I directors were elected to three-year terms expiring at the 2021 Annual Meeting:
- Dennis Fenton, Ph.D.: Received 20,470,135 shares "For" and 68,337 shares "Withheld/Abstaining".
- James Topper, M.D., Ph.D.: Received 16,093,531 shares "For" and 4,444,941 shares "Withheld/Abstaining".
- Ratification of Auditors: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018. The vote resulted in 21,341,401 shares "For" and 29,331 shares "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Confirmation that Dennis Fenton, Ph.D. and James Topper, M.D., Ph.D. have officially assumed their roles as Class I directors.
- Verification that KPMG LLP is the appointed auditor for the fiscal year ending December 31, 2018.
- Review of the significant number of shares withheld/abstaining for the election of James Topper, M.D., Ph.D. (4,444,941 shares) compared to Dennis Fenton, Ph.D. (68,337 shares).